- Home
- EDUC vs EQ Comparison
EDUC vs EQ Comparison
Compare EDUC & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDUC
- EQ
- Stock Information
- Founded
- EDUC 1965
- EQ 2017
- Country
- EDUC United States
- EQ United States
- Employees
- EDUC N/A
- EQ N/A
- Industry
- EDUC Consumer Specialties
- EQ Biotechnology: Pharmaceutical Preparations
- Sector
- EDUC Consumer Discretionary
- EQ Health Care
- Exchange
- EDUC Nasdaq
- EQ Nasdaq
- Market Cap
- EDUC 11.4M
- EQ 12.2M
- IPO Year
- EDUC N/A
- EQ 2018
- Fundamental
- Price
- EDUC $1.31
- EQ $0.34
- Analyst Decision
- EDUC
- EQ Buy
- Analyst Count
- EDUC 0
- EQ 3
- Target Price
- EDUC N/A
- EQ $3.00
- AVG Volume (30 Days)
- EDUC 5.8K
- EQ 1.9M
- Earning Date
- EDUC 07-07-2025
- EQ 08-07-2025
- Dividend Yield
- EDUC N/A
- EQ N/A
- EPS Growth
- EDUC N/A
- EQ N/A
- EPS
- EDUC N/A
- EQ N/A
- Revenue
- EDUC $31,304,000.00
- EQ $30,406,000.00
- Revenue This Year
- EDUC N/A
- EQ N/A
- Revenue Next Year
- EDUC N/A
- EQ N/A
- P/E Ratio
- EDUC N/A
- EQ N/A
- Revenue Growth
- EDUC N/A
- EQ N/A
- 52 Week Low
- EDUC $0.92
- EQ $0.27
- 52 Week High
- EDUC $2.49
- EQ $1.50
- Technical
- Relative Strength Index (RSI)
- EDUC 46.26
- EQ 48.28
- Support Level
- EDUC $1.25
- EQ $0.27
- Resistance Level
- EDUC $1.37
- EQ $0.35
- Average True Range (ATR)
- EDUC 0.07
- EQ 0.05
- MACD
- EDUC -0.01
- EQ 0.00
- Stochastic Oscillator
- EDUC 28.57
- EQ 31.36
About EDUC Educational Development Corporation
Educational Development Corp is the United States trade publisher of the line of educational children's books produced in the United Kingdom. Its business activity functions with two reportable segments: PaperPie and Publishing. The Publishing Division segment markets its products to retail accounts, which include books, school supplies, toy and gift stores and museums, through commissioned sales representatives, trade and specialty wholesalers and an internal telesales group.
About EQ Equillium Inc.
Equillium Inc is a clinical-stage biotechnology company engaged in developing novel therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company intends to commercialize its product candidates either independently or through partnerships, or otherwise monetize its pipeline through strategic transactions. Itolizumab (EQ001), a clinical-stage product candidate, is an anti-CD6 immune-modifying monoclonal antibody, or mAb, that selectively targets the CD6-ALCAM signaling pathway to downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining a balanced immune response. The company's other clinical-stage and pre-clinical-stage candidates include EQ101 and EQ302.